XAIR - Beyond Air affiliate Beyond Cancer doses patient in phase 1 study of ultra-high concentration nitric oxide therapy

• Beyond Air ( NASDAQ: XAIR ) unit Beyond Cancer said on Tuesday the first patient had been treated in a Phase 1 study to assess the safety and immune biomarkers of ultra-high concentration nitric oxide (UNO) for the treatment of solid tumors.
• The company expects initial clinical data from the trial in early 2023.
• The study will evaluate the maximum tolerated dose, safety and immune biomarkers of UNO injection into solid tumors that are not amenable to or have failed standard treatment.
• The primary endpoints of the early-stage study are the incidence and characteristics of adverse events, serious adverse events, dose-limiting toxicities, and changes in safety parameters.
• ( XAIR ) rose ~4% premarket.

For further details see: